feedback

Course Director

John M. Pagel, MD, PhD
John M. Pagel, MD, PhD

Center for Blood Disorders and Stem Cell Transplantation
Swedish Cancer Institute
Seattle, Washington

Faculty

Matthew S. Davids
Matthew S. Davids, MD, MMSc

Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Krish Patel
Krish Patel, MD

Swedish Cancer Institute
Center for Blood Disorders and Stem Cell Transplantation
Seattle, Washington

Accredited by

Penn State College of Medicine

View Activity Materials

Activity Description and Educational Objectives

In this activity, leading hematology-oncology experts discuss therapeutic innovations in a range of B-cell cancers, including chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL), and how community-based professionals can address the challenges of an increasingly complex B-cell cancer treatment landscape. The panel shares a series of practical insights on the continued validation and emergence of targeted therapy (such as BTK, BCL-2, PI3K, and EZH2 inhibitors) and other innovative options in diseases as diverse as CLL, MCL, FL, and DLBCL.

Upon completion of this activity, participants should be better able to:
  • Summarize the current treatment role of targeted therapies and other innovative agents across a range of B-cell cancer settings and patient populations
  • Cite updated safety and efficacy evidence on novel therapeutics, including single-agent and combination regimens, in patients with cancers such as CLL, FL, MCL, and DLBCL
  • Select personalized therapy with novel therapeutics for patients with treatment-naïve or relapsed/refractory B-cell cancers
  • Develop appropriate adverse event management strategies for patients with B-cell cancers who are experiencing toxicity while on therapy with newer therapeutics

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists and other clinicians involved in the management of B-cell cancers.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: August 25, 2020 - August 24, 2021
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Chair

John M. Pagel, MD, PhD
Chief of Hematologic Malignancies
Director of Hematopoietic Stem Cell Transplantation Program
Center for Blood Disorders and Stem Cell Transplantation
Swedish Cancer Institute
Seattle, Washington

John M. Pagel, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; BeiGene; Gilead Sciences, Inc.; and Loxo Oncology.

Faculty

Matthew S. Davids, MD, MMSc
Associate Professor of Medicine, Harvard Medical School
Director, Clinical Research, Lymphoma Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Matthew S. Davids, MD, MMSc, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbvie Inc.; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene; Celgene Corporation; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; MEI Pharma Inc.; Pharmacyclics LLC; TG Therapeutics; Verastem, Inc.; and Zentalis Pharmaceuticals.
Grant/Research Support from Abbvie Inc.; Ascentage Pharma; AstraZeneca; Genentech, Inc.; MEI Pharma Inc.; Pharmacyclics LLC; Surface Oncology; TG Therapeutics; and Verastem, Inc.

Krish Patel, MD
Director, Lymphoma Program
Center for Blood Disorders and Stem Cell Transplantation
Swedish Cancer Institute
Seattle, Washington

Krish Patel, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; BeiGene; Bristol Myers Squibb/Celgene Corporation; Genentech, Inc.; Kite Pharma; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.
Speakers Bureau participant with AstraZeneca; Bristol Myers Squibb/Celgene Corporation; Genentech, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.

Medical Director

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Providership, Credit, and Support


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6654-21-T.

Providership

This CME activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by educational grants from Epizyme Inc.; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Verastem Oncology.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Penn State College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Penn State College of Medicine.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2020, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.